Some big drugs see big changes, but most stable in Q2 drug prices

Why This Topic Matters

Quarterly ASP updates can affect payment limits and reimbursement expectations for frequently billed drugs. Readers who work with Medicare drug claims or drug pricing trends can use this article to understand the scope of changes in the Q2 2013 CMS list and identify which categories of drugs saw meaningful movement.

Article Sections

1. Drug pricing

   Overview of CMS’s quarterly ASP list update and the general pattern of price movement across the drug list.

2. Q2 adjustments blunt Q1 changes

   Discussion of how second-quarter adjustments offset earlier first-quarter price movements and how the overall distribution of increases and decreases looked across the list.

3. Only two drugs cut

   Summary of stability among selected higher-profile drugs and the limited number of list deletions and additions in the quarter.